XML 54 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debt - Narrative (Details)
1 Months Ended 3 Months Ended 48 Months Ended
Jan. 30, 2013
USD ($)
d
$ / shares
Feb. 28, 2018
USD ($)
$ / shares
Nov. 30, 2015
USD ($)
Apr. 30, 2015
d
conversion_right
$ / shares
Mar. 31, 2018
USD ($)
institution
Mar. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
shares
Dec. 31, 2017
USD ($)
institution
Debt Instrument [Line Items]                
Gain on embedded derivative           $ 3,200,000    
Fair value of embedded derivative           $ 13,600,000    
Reversal of gains on embedded derivative         $ 0      
Credit line capacity         197,411,000      
Goodwill         $ 719,891,000     $ 717,099,000
Number of financial institutions | institution         11     11
BioReference                
Debt Instrument [Line Items]                
Net assets         $ 900,000,000      
Goodwill         401,800,000      
Intangible assets         $ 436,000,000      
OPKO Health Europe                
Debt Instrument [Line Items]                
Weighted average interest rate         2.50%     3.00%
Minimum | OPKO Health Europe                
Debt Instrument [Line Items]                
Variable interest rates         1.76%      
Maximum | OPKO Health Europe                
Debt Instrument [Line Items]                
Variable interest rates         6.26%      
Senior Notes | Notes Due February 1, 2033                
Debt Instrument [Line Items]                
Interest rate on notes payable 3.00%              
Debt face amount $ 175,000,000.0              
Equivalent redemption price 100.00%              
Notes | Notes Due February 1, 2033                
Debt Instrument [Line Items]                
Conversion price per share (in dollars per share) | $ / shares $ 7.07     $ 7.07        
Conversion rate 0.14148     0.1414827        
Equivalent redemption price 100.00%              
Convertible debt, threshold percentage of stock price trigger 130.00%     130.00%        
Number of trading days | d       20        
Number of consecutive trading days applicable conversion price | d       30        
Common stock trigger price (in dollars per share) | $ / shares       $ 9.19        
Conversion right triggered | conversion_right       1        
Notes | Notes Due February 1, 2033 | Minimum                
Debt Instrument [Line Items]                
Number of trading days | d 20              
Notes | Notes Due February 1, 2033 | Maximum                
Debt Instrument [Line Items]                
Number of consecutive trading days applicable conversion price | d 30              
Notes | Notes Due February 1, 2033 | On or after February 1, 2017 and before February 1, 2019                
Debt Instrument [Line Items]                
Equivalent redemption price 100.00%              
Notes | Notes Due February 1, 2033 | On or after February 1, 2019                
Debt Instrument [Line Items]                
Equivalent redemption price 100.00%              
Convertible Debt | 5% Convertible Notes                
Debt Instrument [Line Items]                
Interest rate on notes payable   5.00%            
Debt face amount   $ 55,000,000.0            
Maturity duration   5 years            
Par value per converted share (in dollars per share) | $ / shares   $ 0.01            
Conversion price per share (in dollars per share) | $ / shares   $ 5.00            
Minimum conversion notice   30 days            
Maximum conversion notice   60 days            
Convertible Debt | Notes Due February 1, 2033                
Debt Instrument [Line Items]                
Converted debt amount             $ 143,200,000.0  
Line of Credit                
Debt Instrument [Line Items]                
Weighted average interest rate         4.10%     4.20%
Revolving Credit Facility | Line of Credit | New Credit Agreement                
Debt Instrument [Line Items]                
Credit line capacity     $ 175,000,000.0          
Higher borrowing capacity option     $ 275,000,000.0          
Remaining borrowing capacity         $ 12,700,000      
Commitment fee percentage     0.50%          
Swingline | Line of Credit | New Credit Agreement                
Debt Instrument [Line Items]                
Credit line capacity     $ 20,000,000.0          
Letter of Credit | Line of Credit | New Credit Agreement                
Debt Instrument [Line Items]                
Credit line capacity     $ 20,000,000.0          
LIBOR | Revolving Credit Facility | Line of Credit | New Credit Agreement                
Debt Instrument [Line Items]                
Basis spread on variable rate     2.50%          
LIBOR, First 12 Months | Revolving Credit Facility | Line of Credit | New Credit Agreement                
Debt Instrument [Line Items]                
Basis spread on variable rate     0.35%          
LIBOR Thereafter | Revolving Credit Facility | Line of Credit | New Credit Agreement                
Debt Instrument [Line Items]                
Basis spread on variable rate     0.50%          
LIBOR, First 12 Months, Adjusted for Eurocurrency Liabilities | Revolving Credit Facility | Line of Credit | New Credit Agreement                
Debt Instrument [Line Items]                
Basis spread on variable rate     1.35%          
LIBOR, Thereafter, Adjusted for Eurocurrency Liabilities | Revolving Credit Facility | Line of Credit | New Credit Agreement                
Debt Instrument [Line Items]                
Basis spread on variable rate     1.50%          
Common Stock | Convertible Debt | Notes Due February 1, 2033                
Debt Instrument [Line Items]                
Shares issued on converted debt (in shares) | shares             21,539,873